"Probiotics have been in the spotlight for years for their beneficial effects on digestive health. Recently, scientists have discovered even more ways for probiotics to improve health, including benefits connected to athletic performance and exercise endurance. We are excited to collaborate with Kaged Muscle, innovators within the sports nutrition field, to bring one of the latest health ingredients to the market."
"Our customers are more conscious of what is included in the supplements they use to fuel their workouts. We were impressed with the TWK10® ingredient, due to its substantial effects in athletes of all levels; but also because it embodies a clean and naturally sourced ingredient, as it was originally isolated from food-based sources."
Greenwood, USA and Basel, Switzerland, 30 June 2021 – Kaged Muscle, a sports nutrition company based in Huntington Beach, California, and Lonza today announced a collaboration to bring Lonza's new probiotic ingredient, specifically for sports nutrition, to the US market.
TWK10® sports probiotic helps answer growing consumer demands for clean-label, naturally sourced and clinically proven dietary supplements and ingredients. Originally sourced from Taiwanese kimchi, this unique form of the L. plantarum strain is the first probiotic formulated to address athletes' health, performance and endurance at all levels.
Kaged Muscle will launch Pro-biotic Premium Performance as part of its product lines focused on endurance and active living. The company sells products with additional Lonza health ingredients, including Carnipure® L-Carnitine and ChromeMate® ingredients.
Kaged Muscle's Pro-biotic will be formulated using the Capsugel® DRcaps® capsules, which feature a modified release profile ideal for the targeted release of probiotics in the gut. Unlike traditional capsules designed to open the contents within the stomach, DRcaps® capsules feature a uniquely designed release approach, ensuring maximum delivery of living probiotics to where they can be absorbed best.
For more information about Lonza's health ingredients and dosage form solutions, including innovative capsules, visit www.capsugel.com.
TWK10 is a Synbio Tech trademark.
1. Huang, et al., (2018). Effect of Lactobacillus Plantarum TWK10 on Improving Endurance Performance in Humans. The Chinese journal of physiology, 61(3), 163–170. https://pubmed.ncbi.nlm.nih.gov/29962176/
Exhaustive time with VO2 workload; Improvement level based on 6 week study; n=16, 8 individuals compared to baseline.
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector.
Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion. Find out more at www.lonza.com.
Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter
Kaged Muscle is proud to be a supplement line of deep integrity, sourcing the purest, most potent raw materials. We perform rigorous laboratory and real-world testing, adhere to third-party quality assurance practices and have an unwavering commitment to quality and safety.
Our mission at Kaged Muscle is simple: to deliver scientifically backed, superior, but affordable products that contain the highest quality ingredients and utilize the most innovative technologies.
Dr. Martina Ribar Hestericová
Trade Media Lead
Lonza Group Ltd
Tel +41 61 316 8982
Lonza Group Ltd
Tel +41 79 421 1609
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.